Tropocells System

Pure PRP
for Maximal Results

Cellenis® PRP
SKIN REJUVENATION

Cellenis[R] PRP is prepared using the latest, advanced gel filtration technology.

Cellenis[R] patented gel filtration system eliminates undesired erythrocytes, which have been shown to significantly decrease fibroblast proliferation and augment apoptosis in vitro[1].

The Cellenis[R] system virtually eliminates granulocytes as well, which are considered not beneficial in terms of the regeneration process, and may contribute to a catabolic effect by secreting catabolic mediators, including metalloproteinases[2].

Cellenis[R] PRP enables the clinician to concentrate platelets and growth factors between 1.8 - 10 fold over whole blood base line.

All desired white blood cells (i.e. mononuclear cells) and peripheral blood stem cells are included, the latter at a concentration between 2.5-5 over the concentration in whole blood.

1 Red Blood Cells Inhibit Proliferation and Stimulate Apoptosis in Human Lung Fibroblasts In Vitro Fredriksson K et al. Scand J Immunol. 2004
2 Growth Factor and Catabolic Cytokine Concentrations Are Influenced by the Cellular. Composition of Platelet-Rich Plasma. Sundman et al. Am J Sports Med. 2011

PROVEN PERFORMANCE

Tested to evaluate biocompatibility, platelet yield, growth factors availability (PDGF, EGF and VEGF), platelet in vitro-characteristics and viability (platelet aggregation, p-selectin and hypotonic stress) immediately vs. four hours after preparation.



Hematological analyses of PRP vs. Whole Blood. (A-B) Stained whole blood smears containing numerous erythrocytes and leukocytes. Conversely, PRP smears (C, D) contain primarily platelets (arrow), while the erythrocytes and granulocytes are eliminated.

Cellenis[R] PRP	
Platelets concentration fold	X 4 - 5
RBC (10^6/ul)	0.0
WBC (10^3/ul)	0.2
• Granulocytes	8.5% from WBC
• Mononuclear cells	86.2% from WBC
PDGF (pg/ml)	2048
VEGF (pg/ml)	220
EGF (pg/ml)	269

QUALITY ASSURANCE

Cellenis[R] System is a CE Class IIb medical device and USFDA 510K approved and cleared.
Manufactured in compliance with EN ISO 13485:2003, ISO 9001:2008 international standards.

MEDIRA
SPECIALISING IN BIOMATERIALS

CE 1023

T 0800 292 2014 www.medira.co.uk/cellenis email info@medira.co.uk